Tau and neurodegeneration.

Autor: Goedert M; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK., Crowther RA; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK., Scheres SHW; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK., Spillantini MG; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Jazyk: angličtina
Zdroj: Cytoskeleton (Hoboken, N.J.) [Cytoskeleton (Hoboken)] 2024 Jan; Vol. 81 (1), pp. 95-102. Date of Electronic Publication: 2023 Dec 10.
DOI: 10.1002/cm.21812
Abstrakt: First identified in 1975, tau was implicated in Alzheimer's disease 10 years later. Filamentous tangle inclusions were known to be made of hyperphosphorylated tau by 1991, with similar inclusions gaining recognition for being associated with other neurodegenerative diseases. In 1998, mutations in MAPT, the gene that encodes tau, were identified as the cause of a dominantly inherited form of frontotemporal dementia with abundant filamentous tau inclusions. While this result indicated that assembly of tau into aberrant filaments is sufficient to drive neurodegeneration and dementia, most cases of tauopathy are sporadic. More recent work in experimental systems showed that filamentous assemblies of tau may first form in one brain area, and then spread to others in a prion-like fashion. Beginning in 2017, work on human brains using high-resolution techniques has led to a structure-based classification of tauopathies, which has opened the door to a better understanding of the significance of tau filament formation.
(© 2023 MRC Laboratory of Molecular Biology and The Authors. Cytoskeleton published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: